Hepatitis/MASH

Organ transplant recipients who received infected kidneys were cured of hepatitis C after taking antiviral therapy following the procedure.

Study offers insight into the evolution of global dissemination of hepatitis B virus genotypes D and A.

The FDA has approved updates to the labeling for hepatitis C virus (HCV) drug glecaprevir and pibrentasvir (Mavyret) to include new data from 2 clinical studies.

The revised labeling for glecaprevir and pibrentasvir (Mavyret) includes data from clinical trials on the safety and efficacy of the treatment for HIV-1 coinfected patients and liver and kidney transplant recipients.

Interaction between hepatitis C virus and high alcohol consumption significantly limits patient survival.

Silvestrol inhibited the replication of pathogens in both cell cultures and in a mouse model.

The FDA has granted approval to a pair of assays designated for the use with an immunodiagnostic system that detects hepatitis B (HBV) in individuals.

Hepatitis B virus core inhibitor under evaluation in a pair of global phase 2a proof of concept studies.

Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses some of the challenges in treating patients who acquired hepatitis C virus from injection drug use.

Top news of the week from Specialty Pharmacy Times.

Researchers estimated whether a hepatitis C vaccine could reduce transmission of the virus among injection drug users, even without providing complete immunity.

Taking advantage of cost-effective generic medications can improve access to hepatitis B treatment, especially in countries with a high disease burden.

Top news of the day from across the health care landscape.

A new study provides insight into previously unknown details about the capsid that may have implications for the development of new drugs to treat the infection.

A new, inexpensive diagnostic test can help identify patients who require immediate treatment for hepatitis B virus across Africa.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape

Patients with both private and public insurers face high denial rates across the United States for life-saving hepatitis C drugs, despite changes in restrictions and increased price competition.

The hepatitis C virus (HCV) guidelines for unique populations have recently been updated.

Access to diagnosis and treatment must be improved worldwide to meet target goals for the elimination of viral hepatitis.

US report indicates new drivers of death have emerged over time and have continued to unequally affect residents at the state level.

Black patients may be eligible for a shorter course of hepatitis C virus treatment.

A recently-discovered hepatitis C virus subtype may complicate treatment.